ZA908768B - A method of treating anxiety related disorders using sertraline - Google Patents

A method of treating anxiety related disorders using sertraline

Info

Publication number: ZA908768B
Authority: ZA; South Africa
Prior art keywords: sertraline; related disorders; treating anxiety; anxiety related; naphthalenamine
Prior art date: 1989-11-02

Application number

ZA908768A

Other languages

English (en)

Inventor

Declan P Doogan

P Doogan Declan

Karen A Scappaticci

A Scappaticci Karen

Elizabeth Hackett

Hackett Elizabeth

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-02

Filing date

1990-11-01

Publication date

1992-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23710001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA908768(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-11-01 Application filed by Pfizer filed Critical Pfizer

1992-06-24 Publication of ZA908768B publication Critical patent/ZA908768B/xx

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 2
208000019901 Anxiety disease Diseases 0.000 title 1
230000036506 anxiety Effects 0.000 title 1
229960002073 sertraline Drugs 0.000 title 1
206010041250 Social phobia Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA908768A 1989-11-02 1990-11-01 A method of treating anxiety related disorders using sertraline ZA908768B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/431,000 US4962128A (en)	1989-11-02	1989-11-02	Method of treating anxiety-related disorders using sertraline

Publications (1)

Publication Number	Publication Date
ZA908768B true ZA908768B (en)	1992-06-24

Family

ID=23710001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA908768A ZA908768B (en)	1989-11-02	1990-11-01	A method of treating anxiety related disorders using sertraline

Country Status (17)

Country	Link
US (1)	US4962128A (da)
EP (4)	EP1127571B1 (da)
JP (1)	JPH03153624A (da)
KR (1)	KR960016580B1 (da)
AT (3)	ATE212223T1 (da)
AU (1)	AU616127B2 (da)
CA (1)	CA2029065C (da)
DE (3)	DE69033903D1 (da)
DK (3)	DK0429189T3 (da)
HU (1)	HUT59305A (da)
IE (4)	IE903936A1 (da)
IL (1)	IL96146A (da)
MY (1)	MY106075A (da)
NZ (1)	NZ235933A (da)
PH (1)	PH26836A (da)
PT (1)	PT95760B (da)
ZA (1)	ZA908768B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE96999T1 (de) *	1989-08-30	1993-11-15	Pfizer	Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4940731A (en) *	1989-08-30	1990-07-10	Pfizer Inc.	Method of treating premature ejaculation using sertraline
PT98628A (pt) *	1990-08-09	1992-06-30	Massachusetts Inst Technology	Processo de composicoes farmaceuticas a base de por exemplo sertralina
US5457100A (en) *	1991-12-02	1995-10-10	Daniel; David G.	Method for treatment of recurrent paroxysmal neuropsychiatric
US5597826A (en) *	1994-09-14	1997-01-28	Pfizer Inc.	Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5525347A (en) *	1995-01-31	1996-06-11	Medical University Of South Carolina	Composition and methods for treating performance anxiety
US20040208926A1 (en) *	1997-07-01	2004-10-21	Pfizer Inc	Solubilized sertraline compositions
AU761618B2 (en) *	1997-07-01	2003-06-05	Pfizer Inc.	Sertraline salts and sustained-release dosage forms of sertraline
US20030133974A1 (en) *	1997-07-01	2003-07-17	Curatolo William John	Encapsulated solution dosage forms of sertraline
HUP0002296A3 (en)	1997-07-01	2001-11-28	Pfizer	Sertraline salts and sustained-release dosage forms of sertraline
US6391922B1 (en)	1998-01-13	2002-05-21	Synchroneuron, Llc	Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
DE19830201A1 (de) *	1998-07-07	2000-01-13	Boehringer Ingelheim Pharma	Mittel mit antidepressiver Wirkung
WO2000021521A2 (en) *	1998-10-13	2000-04-20	Pfizer Products Inc.	Sertraline oral concentrate
US6727283B2 (en) *	1998-10-13	2004-04-27	Pfizer Inc.	Sertraline oral concentrate
IL132500A0 (en)	1998-10-29	2001-03-19	Pfizer Prod Inc	Stereoselective microbial reduction of a racemic tetralone
US6245782B1 (en)	1999-05-17	2001-06-12	Heartdrug Research L.L.C.	Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
CA2395231C (en)	1999-12-23	2006-08-15	Pfizer Products Inc.	Hydrogel-driven layered drug dosage form
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама
US20030119908A1 (en) *	2001-12-21	2003-06-26	Zambon Group S.P.A.	Stable gabapentin compositions
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
US20040131672A1 (en) *	2003-01-07	2004-07-08	Nilobon Podhipleux	Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US20050070577A1 (en) *	2003-07-03	2005-03-31	Pfizer Inc.	Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
CA2567249A1 (en) *	2004-04-19	2006-10-05	Jds Pharmaceuticals, Llc	Lithium combinations, and uses related thereto
US20050250738A1 (en) *	2004-05-06	2005-11-10	Mosher Gerold L	Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US7893053B2 (en) *	2006-06-16	2011-02-22	Theracos, Inc.	Treating psychological conditions using muscarinic receptor M1 antagonists
US20060257475A1 (en) *	2006-08-17	2006-11-16	Boehringer Ingelheim International Gmbh	Stable Sertraline Hydrochloride Formulation and Method
GB0708818D0 (en) *	2007-05-08	2007-06-13	Portela & Ca Sa	Compounds
WO2010094074A1 (en) *	2009-02-20	2010-08-26	Palmaya Pty Ltd	Pharmaceutical preparation and delivery system
US20100298397A1 (en) *	2009-05-19	2010-11-25	Singh Nikhilesh N	Method of treatment of obsessive compulsive disorder with ondansetron
EP2875810A1 (en) *	2013-11-20	2015-05-27	Biocodex	Pharmacological treatment of obsessive-compulsive disorder using Stiripentol or a similar compound
GB2630572A (en)	2023-05-29	2024-12-04	Novumgen Ltd	An orally disintegrating tablet of sertraline and its process of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536518A (en) *	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4803076A (en) *	1986-09-04	1989-02-07	Pfizer Inc.	Controlled release device for an active substance
ATE175358T1 (de) *	1987-10-22	1999-01-15	Massachusetts Inst Technology	Behandlung des prämenstruellen oder späten lutealsphase-syndroms
IL91398A (en) *	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane

1989
- 1989-11-02 US US07/431,000 patent/US4962128A/en not_active Expired - Lifetime
1990
- 1990-10-28 IL IL9614690A patent/IL96146A/en not_active IP Right Cessation
- 1990-10-29 DK DK90311797T patent/DK0429189T3/da active
- 1990-10-29 AT AT90311797T patent/ATE212223T1/de not_active IP Right Cessation
- 1990-10-29 EP EP01103962A patent/EP1127571B1/en not_active Revoked
- 1990-10-29 EP EP90311797A patent/EP0429189B1/en not_active Revoked
- 1990-10-29 AT AT01103962T patent/ATE269068T1/de not_active IP Right Cessation
- 1990-10-29 EP EP01103959A patent/EP1129708B1/en not_active Revoked
- 1990-10-29 DE DE69033903T patent/DE69033903D1/de not_active Revoked
- 1990-10-29 PH PH41458A patent/PH26836A/en unknown
- 1990-10-29 AT AT01103959T patent/ATE327743T1/de not_active IP Right Cessation
- 1990-10-29 EP EP01103963A patent/EP1125581A1/en not_active Ceased
- 1990-10-29 DK DK01103959T patent/DK1129708T3/da active
- 1990-10-29 DE DE69034223T patent/DE69034223T2/de not_active Revoked
- 1990-10-29 DE DE69034149T patent/DE69034149T2/de not_active Revoked
- 1990-10-29 DK DK01103962T patent/DK1127571T3/da active
- 1990-10-31 PT PT95760A patent/PT95760B/pt not_active IP Right Cessation
- 1990-10-31 CA CA002029065A patent/CA2029065C/en not_active Expired - Lifetime
- 1990-10-31 JP JP2295130A patent/JPH03153624A/ja active Pending
- 1990-11-01 IE IE393690A patent/IE903936A1/en not_active IP Right Cessation
- 1990-11-01 KR KR1019900017691A patent/KR960016580B1/ko not_active Expired - Fee Related
- 1990-11-01 MY MYPI90001915A patent/MY106075A/en unknown
- 1990-11-01 ZA ZA908768A patent/ZA908768B/xx unknown
- 1990-11-01 NZ NZ235933A patent/NZ235933A/en unknown
- 1990-11-01 AU AU65715/90A patent/AU616127B2/en not_active Ceased
- 1990-11-01 IE IE20020410A patent/IE20020410A1/en not_active IP Right Cessation
- 1990-11-01 IE IE20020409A patent/IE20020409A1/en unknown
- 1990-11-01 IE IE20020411A patent/IE20020411A1/en unknown
- 1990-11-02 HU HU907011A patent/HUT59305A/hu unknown

Also Published As

Publication number	Publication date
NZ235933A (en)	1997-07-27
EP0429189A2 (en)	1991-05-29
IL96146A (en)	1995-10-31
PH26836A (en)	1992-11-05
KR910009252A (ko)	1991-06-28
DE69034223T2 (de)	2006-11-02
IE20020409A1 (en)	2002-11-27
AU616127B2 (en)	1991-10-17
DE69034149D1 (de)	2004-07-22
ATE327743T1 (de)	2006-06-15
IE20020411A1 (en)	2002-11-27
US4962128A (en)	1990-10-09
AU6571590A (en)	1991-08-01
DK0429189T3 (da)	2002-02-11
DE69034149T2 (de)	2004-09-30
CA2029065C (en)	1994-11-08
PT95760A (pt)	1991-09-13
IE903936A1 (en)	1991-05-08
EP1129708B1 (en)	2006-05-31
JPH03153624A (ja)	1991-07-01
ATE212223T1 (de)	2002-02-15
ATE269068T1 (de)	2004-07-15
IE20020410A1 (en)	2002-11-27
DE69034223D1 (de)	2006-07-06
PT95760B (pt)	1997-12-31
DK1127571T3 (da)	2004-09-20
EP0429189A3 (en)	1992-01-22
KR960016580B1 (ko)	1996-12-16
EP1127571A1 (en)	2001-08-29
EP0429189B1 (en)	2002-01-23
CA2029065A1 (en)	1991-05-03
HUT59305A (en)	1992-05-28
DE69033903D1 (de)	2002-03-14
IL96146A0 (en)	1991-07-18
MY106075A (en)	1995-03-31
EP1129708A1 (en)	2001-09-05
DK1129708T3 (da)	2006-08-07
EP1127571B1 (en)	2004-06-16
EP1125581A1 (en)	2001-08-22
HU907011D0 (en)	1991-05-28

Publication	Publication Date	Title
EP0429189A3 (en)	1992-01-22	A method of treating anxiety related disorders using sertraline
MY106938A (en)	1995-08-30	Method of treating premature ejaculation using sertraline
TW207537B (da)	1993-06-11
KR880012218A (ko)	1988-11-26	캘폰 유도체를 사용한 다발성 경화증의 치료방법
EP0393766A3 (en)	1991-11-06	New 3-n substituted carbamoyl-indole derivatives
BR9508295A (pt)	1998-01-13	Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina
KR890011589A (ko)	1989-08-21	벤즈아미드의 용도
BR0111897A (pt)	2003-05-13	Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
MY106939A (en)	1995-08-30	A method of treating chemical dependencies using sertraline.
ZA966027B (en)	1998-01-16	The use of sertraline to treat post myocardial infarction patients.
IL89082A0 (en)	1989-08-15	Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
ATE80998T1 (de)	1992-10-15	Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
EP0760013A4 (en)	1997-12-10	TREATMENT OF INFLUENZA VIRUS INFECTION WITH HEMAGGLUTININ ACYLATION / PALMITYLATION INHIBITING ANTIVIRALS
ZA89574B (en)	1989-09-27	Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system